UK Clarifies RWD Collection Rules Under Early Access Scheme
Executive Summary
New UK guidance says companies do not have to apply for clinical trial approval or ethics review to collect data on the clinical management of patients receiving unapproved drugs under an early access scheme. However, consent is needed where such data may have research value once collected.
You may also be interested in...
UK’s Early Access To Medicines Scheme To Get New Legal Basis
Legal clarity around the core principles of the UK’s early patient access scheme is expected to benefit the pharma industry, patients and healthcare professionals.
UK MHRA Specifies Eligibility For Consultancy Firms To Monitor GMP, GDP Compliance
Consultancy firms must have at least five years of experience in carrying out independent GMP or GDP audits if they want to apply to become a “compliance monitor” under a new MHRA scheme to keep track of drug companies that fail to comply with GMP/GDP requirements.
Digital Data Deluge Can Affect Oversight Of Patient Safety In Trials
The digitalization of clinical trials is generating more patient safety data than companies can process. A senior EMA official says sponsors should carefully select what is needed to maintain appropriate subject oversight by “getting the science right.”